JPWO2023016826A5 - - Google Patents

Info

Publication number
JPWO2023016826A5
JPWO2023016826A5 JP2024506860A JP2024506860A JPWO2023016826A5 JP WO2023016826 A5 JPWO2023016826 A5 JP WO2023016826A5 JP 2024506860 A JP2024506860 A JP 2024506860A JP 2024506860 A JP2024506860 A JP 2024506860A JP WO2023016826 A5 JPWO2023016826 A5 JP WO2023016826A5
Authority
JP
Japan
Prior art keywords
antibody
seq
oligomeric
antibodies
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024506860A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024530021A5 (https=
JP2024530021A (ja
Publication date
Priority claimed from PCT/EP2022/052148 external-priority patent/WO2022162203A1/en
Application filed filed Critical
Priority claimed from PCT/EP2022/071294 external-priority patent/WO2023016826A2/en
Publication of JP2024530021A publication Critical patent/JP2024530021A/ja
Publication of JPWO2023016826A5 publication Critical patent/JPWO2023016826A5/ja
Publication of JP2024530021A5 publication Critical patent/JP2024530021A5/ja
Pending legal-status Critical Current

Links

JP2024506860A 2021-08-05 2022-07-28 治療用抗体の増強のための方法及び手段 Pending JP2024530021A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP21189996.8 2021-08-05
EP21189996 2021-08-05
PCT/EP2022/052148 WO2022162203A1 (en) 2021-01-28 2022-01-28 Method and means for modulating b-cell mediated immune responses
EPPCT/EP2022/052148 2022-01-28
PCT/EP2022/071294 WO2023016826A2 (en) 2021-08-05 2022-07-28 Method and means for enhancing therapeutic antibodies

Publications (3)

Publication Number Publication Date
JP2024530021A JP2024530021A (ja) 2024-08-14
JPWO2023016826A5 true JPWO2023016826A5 (https=) 2025-08-04
JP2024530021A5 JP2024530021A5 (https=) 2025-08-04

Family

ID=84331532

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024506860A Pending JP2024530021A (ja) 2021-08-05 2022-07-28 治療用抗体の増強のための方法及び手段

Country Status (8)

Country Link
US (1) US20250326863A1 (https=)
EP (1) EP4380616A2 (https=)
JP (1) JP2024530021A (https=)
KR (1) KR20240042011A (https=)
CN (1) CN117120084A (https=)
AU (1) AU2022325425A1 (https=)
CA (1) CA3225923A1 (https=)
WO (1) WO2023016826A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024023346A1 (en) * 2022-07-28 2024-02-01 Vaccinvent Gmbh Igm antibodies degrading igg

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ATE296315T1 (de) 1997-06-24 2005-06-15 Genentech Inc Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
WO1999022764A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
WO2000046750A1 (en) 1999-02-05 2000-08-10 Samsung Electronics Co., Ltd. Image texture retrieving method and apparatus thereof
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
CN100427603C (zh) 1999-10-04 2008-10-22 麦迪卡格公司 调控外源基因转录的方法
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
CA2388245C (en) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. The use of serum-free adapted rat cells for producing heterologous polypeptides
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
ES2639222T5 (es) 2000-10-06 2023-11-24 Kyowa Kirin Co Ltd Células que producen unas composiciones de anticuerpo
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7595378B2 (en) * 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
EP2180044A1 (en) 2001-08-03 2010-04-28 GlycArt Biotechnology AG Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity
US7230167B2 (en) 2001-08-31 2007-06-12 Syngenta Participations Ag Modified Cry3A toxins and nucleic acid sequences coding therefor
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US20040132140A1 (en) 2002-04-09 2004-07-08 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
CA2481920A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Antibody composition-containing medicament
EA200401325A1 (ru) 2002-04-09 2005-04-28 Киова Хакко Когио Ко., Лтд. Клетки с модифицированным геномом
US20040259150A1 (en) 2002-04-09 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
JP4832719B2 (ja) 2002-04-09 2011-12-07 協和発酵キリン株式会社 FcγRIIIa多型患者に適応する抗体組成物含有医薬
ATE503829T1 (de) 2002-04-09 2011-04-15 Kyowa Hakko Kirin Co Ltd Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
WO2004029207A2 (en) 2002-09-27 2004-04-08 Xencor Inc. Optimized fc variants and methods for their generation
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP3263596A1 (en) 2002-12-16 2018-01-03 Genentech, Inc. Immunoglobulin variants and uses thereof
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US20080241884A1 (en) 2003-10-08 2008-10-02 Kenya Shitara Fused Protein Composition
JPWO2005035778A1 (ja) 2003-10-09 2006-12-21 協和醗酵工業株式会社 α1,6−フコシルトランスフェラーゼの機能を抑制するRNAを用いた抗体組成物の製造法
ES2672640T3 (es) 2003-11-05 2018-06-15 Roche Glycart Ag Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas
WO2005053742A1 (ja) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
FR2871633A1 (fr) 2004-06-10 2005-12-16 France Telecom Procede de reduction du bruit de phase lors de la reception d'un signal ofdm, recepteur, programme et support
BRPI0513959A (pt) 2004-07-30 2008-05-20 Rinat Neuroscience Corp anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
PE20061323A1 (es) 2005-04-29 2007-02-09 Rinat Neuroscience Corp Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
WO2017024404A1 (en) * 2015-08-10 2017-02-16 Network Immunology Inc. Modification of the immune system by antigen-specific plus antiidiotypic antibodies
US20220356232A1 (en) * 2019-06-28 2022-11-10 Network Immunology Inc. A combination of plasma immunoglobulin and antigen-specific immunoglobulin for the modification of the immune system and the treatment or prevention of autoimmune diseases

Similar Documents

Publication Publication Date Title
RU2663721C1 (ru) Моноклональные антитела к человеческому il-17 и их применение
JP2022037133A (ja) 改良された血清アルブミン結合剤
JP2021526022A5 (https=)
JP7703027B2 (ja) 抗lag-3のモノクローナル抗体、その抗原結合性断片及びその使用
JPWO2019175223A5 (https=)
JP2024105229A5 (https=)
JPWO2019175220A5 (https=)
JPWO2019175217A5 (https=)
JPWO2019175224A5 (https=)
JPWO2019175222A5 (https=)
JPWO2019175215A5 (https=)
JP2021524275A5 (https=)
BG66209B1 (bg) Методи за получаване на антитела с двойна специфичност
JPWO2019228266A5 (https=)
TW202033218A (zh) 多特異性蛋白分子
JP2016512026A (ja) Pan−ELR+CXCケモカイン抗体
KR20120118918A (ko) 인간화 항-emapii 항체 및 이의 용도
CN118702814B (zh) 一种抗ngf单克隆抗体及其应用
CN118165106A (zh) 抗犬il-31单克隆抗体及其应用
TW202214683A (zh) 結合b型肝炎病毒表面抗原的抗體及其應用
JP2019518473A5 (https=)
WO2025152918A1 (zh) 抗cd132抗体及其应用
JPWO2023016826A5 (https=)
JP2022534080A (ja) 新規の抗b型肝炎ウイルス抗体及びその使用
CN117924481A (zh) 抗犬il-31单克隆抗体及其应用